Literature DB >> 20015876

Meta-analysis on hypomethylating agents in myelodysplastic syndromes.

Christine Herbst, Kathrin Bauer, Karl-Anton Kreuzer.   

Abstract

Entities:  

Mesh：

Year:  2009        PMID： 20015876      PMCID： PMC2817043          DOI： 10.3324/haematol.2009.019216

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  5 in total

1.  5-azacitidine prolongs overall survival in patients with myelodysplastic syndrome--a systematic review and meta-analysis.

Authors:  Ronit Gurion; Liat Vidal; Anat Gafter-Gvili; Yulia Belnik; Moshe Yeshurun; Pia Raanani; Ofer Shpilberg
Journal:  Haematologica       Date:  2009-09-22       Impact factor: 9.941

2.  Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia.

Authors:  Bruce D Cheson; Peter L Greenberg; John M Bennett; Bob Lowenberg; Pierre W Wijermans; Stephen D Nimer; Antonio Pinto; Miloslav Beran; Theo M de Witte; Richard M Stone; Moshe Mittelman; Guillermo F Sanz; Steven D Gore; Charles A Schiffer; Hagop Kantarjian
Journal:  Blood       Date:  2006-04-11       Impact factor: 22.113

3.  Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

Authors:  Lewis R Silverman; Erin P Demakos; Bercedis L Peterson; Alice B Kornblith; Jimmie C Holland; Rosalie Odchimar-Reissig; Richard M Stone; Douglas Nelson; Bayard L Powell; Carlos M DeCastro; John Ellerton; Richard A Larson; Charles A Schiffer; James F Holland
Journal:  J Clin Oncol       Date:  2002-05-15       Impact factor: 44.544

4.  Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.

Authors:  Pierre Fenaux; Ghulam J Mufti; Eva Hellstrom-Lindberg; Valeria Santini; Carlo Finelli; Aristoteles Giagounidis; Robert Schoch; Norbert Gattermann; Guillermo Sanz; Alan List; Steven D Gore; John F Seymour; John M Bennett; John Byrd; Jay Backstrom; Linda Zimmerman; David McKenzie; Cl Beach; Lewis R Silverman
Journal:  Lancet Oncol       Date:  2009-02-21       Impact factor: 41.316

5.  Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study.

Authors:  Hagop Kantarjian; Jean-Pierre J Issa; Craig S Rosenfeld; John M Bennett; Maher Albitar; John DiPersio; Virginia Klimek; James Slack; Carlos de Castro; Farhad Ravandi; Richard Helmer; Lanlan Shen; Stephen D Nimer; Richard Leavitt; Azra Raza; Hussain Saba
Journal:  Cancer       Date:  2006-04-15       Impact factor: 6.860
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.